Takafumi Yorozuya Selected Research

HLA-DR14

1/2021

Sarcoidosis development during ulcerative colitis remission in a patient with a susceptible human leukocyte antigen serotype.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takafumi Yorozuya Research Topics

Disease

1	Ulcerative Colitis 01/2021
1	Adenocarcinoma of Lung 01/2021
1	Adenocarcinoma 01/2021
1	Sarcoidosis (Schaumann Disease) 01/2021
1	Carcinoma (Carcinomatosis) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Neoplasms (Cancer) 01/2020
1	Pulmonary Alveolar Proteinosis 07/2019
1	Cough 07/2019

Drug/Important Bio-Agent (IBA)

1	Gefitinib (Iressa)FDA Link 01/2021
1	HLA-B52 AntigenIBA 01/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	HLA-DR14IBA 01/2021
1	HLA-DR15 antigenIBA 01/2021
1	alectinibIBA 01/2021
1	B7-H1 AntigenIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	LigandsIBA 01/2020
1	durvalumabIBA 01/2020
1	PowdersIBA 07/2019
1	Silicon Dioxide (Silica)FDA LinkGeneric 07/2019

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2020
1	Radiotherapy 01/2020
1	Therapeutics 01/2020
1	Chemoradiotherapy 01/2020